1981•PubMedRequires access

[Studies on determining the mutagenicity risk of triethylenetetramine (author's transl)].

N Heinz, Schröder Hf

Abstract

Triethylenetetramine (TETA) is the only available effective drug for the treatment of patients with Wilson's disease and with simultaneous intolerance to D-penicillamine. In the Ames-test, however both TETA and the structurally similar tetramine BE 6184 are mutagenic. The naturally occurring spermine, a closely related tetramine differing only in one additional methylene group in every carbon chain, shows no mutagenicity. TETA does not exhibit any mutagenic potency in the micronucleus-test.

About this research paper

What this paper is about

Why it matters

OpenAlex reports 1 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Key concepts: Triethylenetetramine, Tetramine, Spermine, Chemistry, Micronucleus test, Methylene, Ames test, Pharmacology